{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:06:55Z","timestamp":1789373215482,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.msard.2026.107421","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:12:01Z","timestamp":1785708721000},"page":"107421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tolebrutinib in nonrelapsing SPMS: regulatory divergence and the limits of relapse based labels"],"prefix":"10.1016","volume":"114","author":[{"given":"Tun","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107421_bib0001","unstructured":"Biogen Inc., 2025. Tysabri (natalizumab) prescribing information. DailyMed. Available at: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962 (accessed July 5, 2026)."},{"key":"10.1016\/j.msard.2026.107421_bib0002","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107421_bib0003","series-title":"Cenrifki: EPAR Medicine Overview","year":"2026"},{"key":"10.1016\/j.msard.2026.107421_bib0004","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107421_bib0005","doi-asserted-by":"crossref","first-page":"1132-1140","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107421_bib0006","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107421_bib0007","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107421_bib0008","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1474-4422(06)70410-0","article-title":"Secondary progressive multiple sclerosis: current knowledge and future challenges","volume":"5","author":"Rovaris","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107421_bib0009","article-title":"Drug-induced liver injury: premarketing clinical evaluation","year":"2009","journal-title":"Guid. Ind."},{"key":"10.1016\/j.msard.2026.107421_bib0010","unstructured":"US Food and Drug Administration, 2025. Complete response letter for NDA 219624: tolebrutinib. December 23, 2025. Available at: https:\/\/download.open.fda.gov\/crl\/CRL_NDA219624_20251223.pdf (accessed July 5, 2026)."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:05:21Z","timestamp":1789369521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"alternative-id":["S2211034826004566"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107421","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolebrutinib in nonrelapsing SPMS: regulatory divergence and the limits of relapse based labels","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107421"}}